{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:17:04Z","timestamp":1789035424369,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Patients with non\u2010small cell lung cancer (NSCLC) that harbor driver mutations are associated with a cancer diagnosis at a younger age. While targeted therapies provide deep remissions and durable benefit in a subset of patients, it is unclear whether targeted therapies bridge the gap in years of life lost (YLL) in these younger NSCLC patients with targetable mutations in comparison to generally older NSCLC patients without actionable driver mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Retrospective cross\u2010sectional study using landmark trials leading to the approval of targeted therapies in NSCLC with actionable mutations. We evaluated all targeted therapies as well as chemotherapy and IO regimens for the treatment of NSCLC through FDA Oncology Announcements and NCCN Guidelines for NSCLC (version 4.2021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We estimated the YLL for each driver mutation, cumulative median duration of response (DOR) with targeted therapies by mutation type, and percentage of estimated improvement in YLL from NSCLC targeted therapies. The median ages at diagnosis (in years) for patients whose tumors express targetable mutations were: 47.6 (<jats:italic>NTRK<\/jats:italic>); 52.0 (<jats:italic>ALK<\/jats:italic>); 62.0 (<jats:italic>HER2<\/jats:italic>); 57.0 (<jats:italic>ROS1<\/jats:italic>); 61.4 (<jats:italic>RET<\/jats:italic>); 63.0 (<jats:italic>BRAF<\/jats:italic>); 69.0 (<jats:italic>EGFR<\/jats:italic>); and 72.0 (<jats:italic>MET<\/jats:italic>). For comparison, the median age at diagnosis for patients without driver mutations, regardless of PD\u2010L1 status was 71\u00a0years. The median DOR (in years) for patients whose tumors express the same mutations include: 0.9 (<jats:italic>NTRK<\/jats:italic>); 3.9 (<jats:italic>ALK<\/jats:italic>); 0.6 (<jats:italic>HER2<\/jats:italic>); 6.2 (<jats:italic>ROS1<\/jats:italic>); 2.2 (<jats:italic>RET<\/jats:italic>); 1.5 (<jats:italic>BRAF<\/jats:italic>); 3.1 (<jats:italic>EGFR<\/jats:italic>); and 2.4 (<jats:italic>MET<\/jats:italic>). The median DOR for patients without driver mutations was 1.2\u00a0years. The cumulative estimated survival time (years; median age at diagnosis plus the median DOR or OS) for patients whose tumors express targetable mutations were: 48.5 (<jats:italic>NTRK<\/jats:italic>); 55.9 (<jats:italic>ALK<\/jats:italic>); 62.6 (<jats:italic>HER2<\/jats:italic>); 63.2 (<jats:italic>ROS1<\/jats:italic>); 63.6 (<jats:italic>RET<\/jats:italic>); 64.5 (<jats:italic>BRAF<\/jats:italic>); 72.1 (<jats:italic>EGFR<\/jats:italic>); and 74.4 (<jats:italic>MET<\/jats:italic>). The cumulative estimated survival time for patients without driver mutations, regardless of PD\u2010L1 status, was 72.2\u00a0years of age. We calculated the number of years NSCLC is diagnosed earlier in patients with targetable mutations as follows: 23.4 (<jats:italic>NTRK<\/jats:italic>), 19 (<jats:italic>ALK<\/jats:italic>), 14 (<jats:italic>ROS1<\/jats:italic>), 11 (<jats:italic>EGFR<\/jats:italic>), 9.6 (<jats:italic>RET<\/jats:italic>), 9 (<jats:italic>HER2<\/jats:italic>), and 8 (<jats:italic>BRAF<\/jats:italic>). The percent difference (%) ameliorated in YLL by mutation type is as follows: 44.3 (<jats:italic>ROS1<\/jats:italic>), 28.2 (<jats:italic>EGFR<\/jats:italic>), 22.9 (<jats:italic>RET<\/jats:italic>), 20.5 (<jats:italic>ALK<\/jats:italic>), 18.8 (<jats:italic>BRAF<\/jats:italic>), 6.4 (<jats:italic>HER2<\/jats:italic>), and 3.7 (<jats:italic>NTRK<\/jats:italic>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although targeted therapies have paved the way for significant progress toward providing a survival benefit to many young patients with advanced NSCLC with actionable mutations, it is evident that these therapies still leave a wide gap in the YLL in these younger patients compared to generally older individuals with advanced NSCLC without targetable mutations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4703","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T07:46:13Z","timestamp":1647935173000},"page":"3417-3424","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeted therapy in lung cancer: Are we closing the gap in years of life lost?"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-886X","authenticated-orcid":false,"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine University of California, Irvine Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4482"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S69718"},{"key":"e_1_2_9_6_1","volume-title":"Cancer of the Lung and Bronchus \u2013 Cancer Stat Facts","year":"2021"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S187317"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.478"},{"issue":"355","key":"e_1_2_9_11_1","first-page":"1","article-title":"Mortality in the United States, 2018","author":"Xu J","year":"2020","journal-title":"NCHS Data Brief"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00037","article-title":"Clinicopathologic features of non\u2013small\u2010cell lung cancer harboring an NTRK gene fusion","volume":"2","author":"Farago AF","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.011"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209709"},{"issue":"60","key":"e_1_2_9_15_1","first-page":"2867","article-title":"Metaanalysis of ROS1\u2010positive lung cancer cases","volume":"48","author":"Zinsky R","year":"2016","journal-title":"Eur Respir J"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1046649"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30869"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000625"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz446.018"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.9443"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"issue":"4","key":"e_1_2_9_26_1","first-page":"609","article-title":"Final overall survival and other efficacy and safety results from ASCEND\u20103: phase II study of Ceritinib in ALKi\u2010naive patients with ALK\u2010rearranged NSCLC","volume":"15","author":"Nishio M","year":"2020","journal-title":"J Thorac Oncol off Publ Int Assoc Study Lung Cancer"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00505"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz131"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30690-4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30655-2"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9075"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1603"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9509"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0716-8"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"e_1_2_9_39_1","unstructured":"FDAApproves pralsetinib for metastatic RET fusion\u2013positive NSCLC\u2014the ASCO post.2021. Available from:https:\/\/ascopost.com\/news\/september\u20102020\/fda\u2010approves\u2010pralsetinib\u2010for\u2010metastatic\u2010ret\u2010fusion\u2010positive\u2010nsclc\/"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9504"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00297"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4703","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T19:58:53Z","timestamp":1726862333000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":42,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/cam4.4703"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4703","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"2021-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}